|
1
|
- Aims
- to compare and contrast associations of dimercaptosuccinic acid
(DMSA)-chelatable lead, tibia lead, and blood lead with five
hematopoietic outcomes
- to determine whether polymorphisms in the genes for
δ-aminolevulinic acid dehydratase (ALAD) and the vitamin D
receptor (VDR) modified relations among the lead biomarkers and the
hematopoietic outcomes
|
|
2
|
- Methods
- cross-sectional study of 798 lead workers and 135 non-exposed controls
in Korea
- DMSA-chelatable lead was measured as four-hour urinary lead excretion
after oral administration of 10 mg/kg DMSA
- tibia lead was measured via 109Cd-induced K-shell X-ray
fluorescence (XRF).
|
|
3
|
- Results
- Lead-exposed subjects were 79.6% male, had a mean (SD) age of 40.4
(10.1) years, and a mean (SD) work duration of 8.1 (6.7) years.
- DMSA-chelatable lead levels ranged from 4.8 to 2,103 μg.
- Tibia lead ranged from -7 to 338 μg Pb/g bone mineral
- Blood lead ranged from 4 to 86 μg/dl
|
|
4
|
|
|
5
|
- Results
- After adjustment for covariates
- tibia lead was associated with all five hematopoietic outcomes
- blood lead and DMSA-chelatable lead were associated only with ZPP,
ALAP, and ALAU
- Comparison of regression coefficients, total model adjusted R2
values, and ΔR2 values revealed that:
- blood lead was the best predictor of ZPP, ALAP, and ALAU
- tibia lead was the best predictor of hemoglobin and hematocrit.
|
|
6
|
- Results
- Lead workers with the ALAD2 allele had lower levels of ZPP and ALAP…
- …but there was no clear effect modification by ALAD genotype
- There were no consistent relations of VDR genotype with the
hematopoietic outcomes…
- …nor any apparent effect modification by VDR genotype.
|
|
7
|
- Conclusions
- These observations suggest that lead must have a chronic, cumulative
effect on hemoglobin and hematocrit levels
- any speculated mechanism cannot merely involve short- term plasma or
target organ lead levels
- ALAD and VDR, identified in prior studies to be modifiers of the
toxicokinetics of lead, did not clearly modify associations of measured
lead biomarkers and the hematopoietic outcomes.
|